HilleVax, Inc.

NasdaqGS HLVX

HilleVax, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD -146.24 M

HilleVax, Inc. EBIT is USD -146.24 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -38.13% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

HilleVax, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -105.87 M, a 37.97% change year over year.
HilleVax, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -170.68 M, a -278.90% change year over year.
HilleVax, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -45.05 M.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqGS: HLVX

HilleVax, Inc.

CEO	Dr. Robert M. Hershberg M.D., Ph.D.
IPO Date	April 29, 2022
Location	United States
Headquarters	75 State Street
Employees	90
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Key trends

Past 5 years